Biophan-die neue Microsoft?!

Mal sehen was drauß wird!

LG  

 

Name   Symbol   Market   Type   ISIN   Description   Biophan Techs (BB)  USBB:BIPH  OTC BB  Common Stock

Style LineBarLine (Square)Candlestick Period 1 month2 months3 months6 months1 year2 years3 years5 years

Gruß
leo  

 

  

viel Spaß !

Gruß
leo  

hab mal bei 0,79 Euro den profitablen Rückzug gemacht.

Sorry!

Gruß
leo  

 

http://quotes.barchart.com/texadv.asp?sym=biph

100% buy!!!  

 

Dr. Frank Shellock, Leading Authority on MRI Safety, Joins Biophan Technologies' Scientific Advisory Board
ROCHESTER, N.Y.

Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
       or
Press Interviews:
Michael Weiner, 585-214-2441

MRI Expert Will Provide Guidance as Company Develops Products To Improve MRI Safety and Compatibility for Implants and Devices

Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced the addition of MRI-safety expert Dr. Frank Shellock to the Company's Scientific Advisory Board. The announcement was made by Michael Weiner, CEO of Biophan.

A world-renowned expert on magnetic resonance imaging (MRI) safety for medical applications, Dr. Shellock will provide medical, scientific and market guidance to Biophan as it develops its proprietary technologies into market-ready MRI-enhancing products.

Biophan is a leader in the development of solutions to make MRI safe for use with biomedical devices, such as pacemakers and other implants, and possesses a rich portfolio of intellectual property and technologies that provide proprietary solutions to many of the most significant problems that impact MRI safety and compatibility.

Dr. Shellock has provided testing and consulting services to Biophan during the Company's last five years of research and development. As Biophan prepares to start deploying products in the marketplace, however, Dr. Shellock's advice and perspective will be particularly crucial, said Mr. Weiner.

"As one of the top people in the MRI-safety field, Dr. Shellock has long been one of the most important sources of scientific information for the industry," said Mr. Weiner. "He has a very broad understanding of the medical, scientific and market issues, and will be an invaluable resource for us as a member of our Scientific Advisory Board. It's another very significant honor for us that someone of Dr. Shellock's stature has agreed to serve with the other distinguished members of our Advisory Board."

"I have been working with Biophan since the company's inception, and I have been impressed with the high quality of their technology," said Dr. Shellock. "They are developing numerous important and exciting potential solutions for MRI safety, and as a specialist in the field, I am gratified to be in a position to assist that process."

Dr. Shellock is a physiologist with over 20 years of research experience and more than 18 years of experience in magnetic resonance imaging. He has published widely on the subject, and has authored several of the industry's leading medical textbooks. He is currently an Adjunct Clinical Professor of Radiology and Medicine at the University of Southern California, School of Medicine in Los Angeles, CA and the President of Magnetic Resonance Testing Services in Los Angeles, CA. Dr. Shellock is also the Founder of the Institute for Magnetic Resonance Safety, Education, and Research and is a Fellow of the International Society for Magnetic Resonance in Medicine (ISMRM).

For more information about Biophan and the Company's Scientific Advisory Board, visit the Company's website at www.biophan.com.

Gruß BarCode
 

Business Wire
Zwei neue erteilte Patente und 12 neue Patentanmeldungen festigen die Führungsrolle von Biophan Technologies in der biomedizinischen Technologie
Montag 27. September 2004, 14:18 Uhr



ROCHESTER, N.Y.--(BUSINESS WIRE)--24. Sept. 2004--
Neue Patente bedeuten signifikante Fortschritte bei medizinischen

Anwendungen im weiten Rahmen

Biophan Technologies, Inc. (OTC BB: BIPH), ein Entwickler biomedizinischer Technologie der nächsten Generation meldete heute die Einreichung 12 neuer Patente im Bereich medizinische Anwendungen. Dies festigt die Führungsrolle der Gesellschaft in mehreren wichtigen Bereichen der medizinischen Forschung und im Gesundheitsbereich.

Die vonBiophan und dessen angegliederten Unternehmen Nanoset LLC und Biomed Solutions LLC eingereichten Patente umreißen neue Fortschritte in der Anwendung der Kernspintechnologie (MRI) sowie in den Bereichen Nanotechnologiebeschichtungen, biothermische Batterien und optoelektronische Steuerungen für implantierte medizinische Vorrichtungen.

Die beiden neu erteilten Patente und 12 Anmeldungen erweitern Biophans extensives Portfolio an geistigem Eigentum von 80 auf insgesamt 92 erteilte, anhängige, geschützte oder lizenzierte Patente. Davon sind 21 Patente erteilt und 71 sind anhängig, was eine signifikante Festigung der herausragenden Führungsposition der Gesellschaft bei der Weiterentwicklung biomedizinischer Technologie darstellt.

Die neuen Patente und Anmeldungen betreffen die folgenden Gebiete:

-- Neun der neu eingereichten Patente betreffen die " Anti-Antennen" -Geometrie der Gesellschaft für Stentausführungen; dadurch lassen sich Stents herstellen, die Kernspindarstellungen des Stentinneren nicht behindern. Dies ist vor allem wichtig bei der Diagnose des Heilungsprozesses und beim Nachweis neuer Blockierungen aufgrund von Plaques oder Gewebeansammlungen. Diese Anti-Antennen-Technologie quasi " ent-tunen" die Stents, so dass diese die bei der MRI verwendete Hochfrequenzenergie nicht blockieren. Die neuen Stentausführungen können unabhängig von oder zusammen mit den bereits vorgestellten Nanomagnetbeschichtungen von Biophan verwendet werden, welche die MRI-Bildgebung ebenfalls verbessern. Die Beschichtungen bieten eine weitere Verbesserung der MRI-Bildkompatibilität für Stents.

-- Ein weiteres Patent betrifft ähnliche Anti-Antennen-Designtechniken für Kabel und elektrische Leitungen von medizinischen Vorrichtungen, Katheter und Führungsdrähte für MRI-unterstützte Chirurgie. Das neue Design verhindert unerwünschte Erwärmung dieser Vorrichtungen durch die Hochfrequenzfelder des Kernspingeräts und löst zusammen mit den zuvor erwähnten Technologien Sicherheits- und Bildkompatibilitätsprobleme, welche die Entwicklung von interventioneller Medizin unter Anwendung von Kernspintechnologie bisher blockiert haben.

-- Eine andere Anmeldung erweitert die Technologie der Nanomagnetbeschichtungen der Gesellschaft sowie den zu deren Herstellung und Anwendung eingesetzten Fertigungsprozess.

-- Eine weitere Anmeldung betrifft biothermische Stromquellen für Schrittmacher und andere implantierte Vorrichtungen und erweitert damit die drei, bereits vorhandenen Patente von Biophan in diesem Bereich.

Darüber hinaus erteilte das US-Patentamt am 21. September zwei zuvor eingereichte Anmeldungen von Biophan für Designs, mit denen sich Optoelektronik in Schrittmachern und anderen Implantaten zusammen mit MRI verwenden lässt.

" Diese neuen Patente zeigen sowohl die Tiefe als auch die Geschwindigkeit, mit der Biophan in vielen Bereichen der biomedizinischen Forschung und Gesundheitsversorgung Innovationen entwickelt" , sagte Weiner. " Diese neuen Meilensteine sind wichtig für die Streuung unseres Portfolios an geistigem Eigentum und bieten neue Möglichkeiten zur Entwicklung und zum Wachstum des Erlöses und des Werts des Unternehmens für unsere Anteilsnehmer."

Biophan wird weitere Patente für viele Technologien anmelden, die derzeit zur Lösung der komplexen Probleme in Verbindung mit der MRI-Bildgebung bei Vorhandensein von Implantaten oder chirurgischen Instrumenten entwickelt werden. Dazu gehört eine Reihe von Systemen und Techniken, darunter Optoelektronik, Nanomagnetbeschichtungen, Carbonverbundbeschichtungen, Softwaretechniken und spezialisierte Geometrien von Instrumenten. Diese lassen sich einzeln oder in Kombination verwenden.

Andere Vorrichtungen, die von diesen Techniken profitieren, umfassen Schrittmacher, implantierte Cardioverter-Defibrillatoren, Arzneimittelpumpen, Neurostimulatoren und chirurgischen Instrumente.

Zu den Leistungsverbesserungen, die diese Technologien bieten, gehören die Verringerung oder Eliminierung unerwünschter Erwärmung von Gewebe und Vorrichtungen, die Eliminierung unerwünschter elektrischer Stimulation von Nervengewebe, verbesserte MRI-Bildgebung von ansonsten unsichtbaren Implantaten oder chirurgischen Instrumenten und deutliche Bilddarstellung von Geweben in der Nähe oder innerhalb der Implantate.

Durch die Eliminierung der Probleme und Gefahren, die mit der MRI-Bildgebung dieser Vorrichtungen einhergehen, erweitert Biophan derzeit den Einsatzbereich der Kernspintechnologie, so dass diese auch für Patienten eingesetzt werden kann, die derzeit aus Sicherheitsgründen oder wegen nicht verwendbarem Bildmaterial nicht von dieser wertvollen Technologie profitieren können.

Über Biophan Technologies Biophan Technologies entwickelt und vermarktet neueste Technologien, mit deren Hilfe sich biomedizinische Geräte, beispielsweise Herzschrittmacher und chirurgische und diagnostische Instrumente, sicher und problemlos mit Kernspintomografieausrüstungen betreiben lassen. Das Unternehmen entwickelt Einsatztechnologien für medizinische Implantatsysteme, wie beispielsweise Schrittmacher, und für interventionelle chirurgische Vorrichtungen, wie Katheter und Führungsdrähte, sowie für Stents und andere Implantate, die sich sicher und wirksam durch Kernspintechnologie darstellen lassen. Die Technologie wird außerdem zur Verbesserung von Kernspin-Kontrastmitteln verwendet und wurde auch auf andere Anwendungen erweitert, darunter auf Arzneimitteldelivery- und Energiesysteme durch Körperwärme. Vier Biophan-Produktlinien betreffen Fortschritte in der Nanotechnologie und Thin-Film-Beschichtungen. Biophan konzentriert sich auf Wachstum durch Innovation und einen entwicklungsorientierten Führungsstil. Das Unternehmen und seine Lizenzgeber verfügen über 21 erteilte US-Patente und 71 angemeldete Patente, beispielsweise auf dem Gebiet der Nanotechnologie (Beschichtungen von Nanopartikeln), Hochfrequenzfilter, Polymercomposite, thermoelektrische Materialien für Batterien die Strom aus Körperwärme erzeugen, und Photonik. Biophan arbeitet entwicklungstechnisch mit Boston Scientific (NYSE: BSX) und dem Ames Center for Nanotechnology der NASA zusammen. Es ist das Ziel von Biophan, alle biomedizinischen Geräte sicher und problemlos mit der Kernspintechnologie zu kombinieren und Technologien zur Verbesserung der Lebensqualität zu entwickeln. Mehr Informationen über Biophan gibt es im Internet unter www.biophan.com  

..die 1$ Hürde überspringen.  

Hallo,
hier der Quartalsbericht von Biph vom 06.10.2004. Das Ding liest sich super:

Form 10QSB for BIOPHAN TECHNOLOGIES INC

6-Oct-2004

Quarterly Report


ITEM 2. PLAN OF OPERATION

We are currently in the development stage of operations and expect to be in that mode for at least the next several quarters. Our primary mission is to develop and commercially exploit technologies for enabling biomedical devices, both implantable and those used in diagnostic and interventional procedures, to be safe (not harm the patient or physician) and compatible (allow effective imaging of the device and its surrounding tissue) with MRI.

We have successfully demonstrated effective solutions for making devices which use long metal wire leads, such as pacemakers, defibrillators, neurostimulators, et al. safe for use with MRI and that these solutions provide a meaningful margin of safety. Our solutions address both the problems of device heating and induced voltages in pacemakers, defibrillators, and neurostimulators, which are the two primary problems associated with the use of MRI for patients with these devices. Today, approximately 3 million people have devices that cause them to be denied access to MRI when needed, due to safety concerns and regulatory (FDA and other) contraindications. If manufacturers of these devices incorporated our solutions into their products, they can be made safe for use with MRI.

Additionally, there is a rapidly growing field of medicine known as minimally invasive surgery, using devices such as guidewires and catheters to do many procedures in cardiology, oncology and other specialties. The majority of procedures are done in catheter labs equipped with X-ray or fluoroscopy devices for imaging and guiding the procedures. Many of these devices do not offer the advantages of tissue visualization and discrimination provided by MRI. The combined problems of device safety (they heat up and may induce electrical stimulation) and the image artifacts created by these devices in MRI, have limited the use of MRI machines in this rapidly growing area of medicine. The desire and need for MRI is demonstrated by the advent of catheter labs which have both X-ray devices for guiding devices into the body, and MRI machines for evaluating progress and observing tissue and results. In these new operating theaters, the patients are moved back and forth on a conveyor belt-like system between the imaging devices.

For the past four years, Biophan has been actively engaged in solving the complex problems associated with device safety and imaging under MRI that cause this odd and expensive combination of devices so that, with the advent of our solutions, the industry now, for the first time, has the choice to develop MRI safe and image compatible devices that can be used with MRI.

Biophan has two solutions for resolving the heating of braided metal wire objects such as pacemaker leads (in which we include pacemaker and defibrillator leads) and neurostimulator leads (including deep brain stimulation, or DBS, systems for Parkinson's and epilepsy; systems for pain control, etc.). One solution is an RF filter, licensed from Johns Hopkins exclusively for implantable devices, which can resolve lead heating (it is the metal wire lead connecting a device to the body that is the cause of most of the MRI safety problems). Additionally, to resolve the problems associated with very long metal wires such as surgical guidewires and catheters, we have been engaged in previously secret work within Biophan to develop " anti-antenna geometries" in these leads. By slightly altering the way the leads are made, we can create self-canceling attributes that resolve the radio frequency related problems that cause the heating in the lead. An additional anti-antenna geometry significantly reduces induced voltages. Together, these solutions allow making an MRI-safe lead and device. Several broad patents for this innovation were filed several years ago, and recently the U.S. Patent and Trademark Office allowed a patent which will issue within the next several weeks. As a result, we have now gone public with our solutions, and we have demonstrated the success of this approach to prospective customers and industry experts. We have begun manufacturing samples of devices modified with this solution, which is extremely cost effective. We have modified a pacemaker lead for a pacemaker company concerned with pacemaker safety, which is currently being evaluated by that company.

This modification of the windings of a metal device has broad application. It can also address a significant limitation associated with virtually all stents, medical devices used to keep vessels open. It is very difficult to see inside the stent to determine if blockage is occurring, once the stent is installed in the body. Currently, no diagnostic systems such as X-ray or fluoroscopy are effectively able to see inside of a stent.

We have demonstrated that we can make stents visible within an MRI machine using this method. It works. Researchers in Europe have also demonstrated at conferences that this approach works, and there are some stents shipping in Europe using this approach. The solution requires a change in the way most stents are made. We recently filed nine continuations of our original patent application, applying this innovation to other devices, such as stents, guidewires and catheters. The stent, guidewire and catheter businesses are very large and have many players who compete with one another for competitive advantage. This solution to both heating and stent imaging has broad implications.

Additionally, our primary work for resolving image artifacts that occur when imaging devices in the body with MRI uses thin film nanomagnetic particle coatings, developed by Nanoset, LLC, in collaboration with Biophan. We recently produced MRI images showing an aluminum rod which could not be seen in the MRI image, and next to it showed two identical rods which were quite visible, as a result of having our thin film coating applied. Additionally, the tip of these rods had a bright " glow" , making it easy to spot in the MRI image. This image is available from our web site at www.biophan.com. This capability is part of the suite of technologies that can help make MRI a viable solution for interventional diagnostics and surgery. Once again, we have a solution that works, covered by both issued and pending patents. We are also working on coatings that can improve visibility under MRI using thin film coatings described above. The advantage of a coating solution is that a manufacturer with a product in the market or in development does not have to radically change the physical design manufacturing process. Thus, the coating solution, which we are pursuing, has broad applications for the rapidly growing stent market.

There is considerable industry interest in these approaches to making devices imageable under MRI. The solution has to be applied to the device itself, and is not something that can be incorporated in the MRI machine. However, the solution is of interest to MRI manufacturers we have met with, all of whom benefit from seeing the aforementioned expansion in the use of MRI for interventional medicine and expanded diagnostics (as with stents, and other applications). MRI is also used extensively in oncology, due to its ability to discriminate tissue types.

Image compatibility also has benefits to the pacemaker device manufacturers. The goal of making pacemakers safe for MRI is to allow a pacemaker patient who may need an MRI scan for staging a cancer operation, and subsequent follow-up, or to diagnose a brain tumor, or back or knee problem, etc. However, a device made safe will still cause a significant image artifact where the pacing lead enters the heart or, in the case of a neurostimulator, where that device lead enters to brain, or the spinal cord, etc. By adding " image compatibility" to a pacemaker made safe, it may be possible to enable a pacemaker patient to one day have an MRI angiogram, and avoid having to have an invasive procedure. Similarly, a patient with a Deep Brain Stimulator (DBS) device can undergo a full power MRI of the brain if their lead is not only safe, but also image compatible.

As a result of the growing awareness of the problems outlined here and our broad patent portfolio, we are seeing an increased interest from the medical device industry in our solutions. We are in various stages of discussions and negotiations with several companies regarding the utilization of our technology. The value to our prospective customers is competitive advantage with the potential to gain increased market share, which is the strategy behind all of Biophan's initiatives.

On June 3, 2004, we acquired a 51% interest in TE Bio LLC, a company developing an implantable biothermal battery using body heat gradients to power medical devices such as pacemakers, defibrillators, and drug pumps. The biothermal battery technology is based on a patented innovation in the utilization of thermoelectric materials, using nanoscale-based, thin-film materials to convert thermal energy produced naturally by the human body into electrical energy. The resulting power can be used to " trickle charge" batteries for medium-power devices such as defibrillators, or directly power low-energy devices like pacemakers. It is enabled by nanotechnology which provides the ability to put thousands and thousands of small semi-conductor nodes that convert heat to electricity in a space about the size of one or two postage stamps. We presented the technology at the NASPE Heart Rhythm Society meeting in San Francisco earlier this year and received substantial industry interest from major device manufacturers. We have recruited several consultants experienced in this technology to assist us in developing it.

Biophan committed $300,000 annually for a three-year period, and marketing and management support to TE Bio, in exchange for Biophan's 51% interest. TE Bio was founded by Biomed Solutions, LLC, an affiliate and the company from which Biophan spun out in December 2000. The independent board members of Biophan evaluated the technology and authorized the acquisition, after conclusion of a third party feasibility study.

To manage the growing R&D and customer interactions in the MRI technology business and the biothermal business, we have expanded our staff to support these projects.

John Lanzafame, an experienced medical device executive, who joined Biophan in September as President of Biophan's new Nanolution division, focused on leveraging recent discoveries in nanotechnology such as Biophan's nanomagnetic particles for the purposes of drug delivery and drug elution from devices. Mr. Lanzafame has 15 years experience in the medical device industry, most recently as President of STS Biopolymers, a company specializing in customized surfaces, including drug eluting coatings for stents and indwelling catheters. STS Biopolymers was acquired in late 2003 by Angiotech Pharmaceuticals, which licensed the use of paclitaxel on stents to Boston Scientific. Mr. Lanzafame has experience in drug delivery, product development and sales and marketing, and will bring his breadth of experience both to the newly formed drug delivery division, as well as to assist in development and marketing of the MRI-related products.

We have retained Tim Bibens, formerly Director of Operations for the Ortho Clinical Diagnostics, a J & J company, and prior to that a Supply Chain Manager at Allied Signal, to oversee our MRI safety and image compatibility projects, reporting to Jeff Helfer, our VP-Engineering.

Sarah Cooper, a research fellow and chemical engineer at NASA's Ames Center for Nanotechnology, has been an active participant in the biothermal battery project. Ms. Cooper's fellowship ends in September 2004, and we have extended an offer to her to work with us as a consultant on the biothermal battery project.

We have retained additional technical consultants to augment our staff's research and development efforts on the MRI safety and compatibility project and the biothermal battery project.

We do most of our thin film coating research and development at Alfred University, in coordination with Nanoset, LLC. To facilitate this, we have helped Alfred construct a clean room facility to be used for our coating experiments and sample preparation.

On June 4, 2004, we announced that we had acquired from New Scale Technologies, Inc. the exclusive worldwide distribution rights for the medical market for New Scale's ceramic " SQUIGGLE(TM) motor" , including the multi-billion dollar drug delivery market. Developed to meet the growing demand for high precision, low cost actuation devices, the motor is currently on the market generating revenues and is available for OEM integration today. The motor uses no metal wire windings (one of the primary causes of image interference under MRI), is capable of both linear and rotational movement, and can move forward and backwards several inches at nanometer increments, thereby providing a controllable drug release environment.

As part of the exclusive distribution agreement, Biophan will provide sales and marketing to the medical device industry on behalf of New Scale and has also made a $100,000 investment in the company for a 10% interest. The motor offers several advantages for driving drug pumps, and other medical applications. Using only four parts (other motors can have as many as 100 parts), it provides a unique combination of high reliability, flexibility, and power consumption advantages. By using ceramic components and no windings, it is very compatible with MRI imaging.

This product also fits in with our strategic plan to be a provider of proprietary new technologies to our OEM customers and prospects. While we continue to provide solutions that will one day enable all biomedical devices to be MRI-safe and image compatible, we have expanded our focus to bring additional, proprietary innovations to our customers. We continue to maintain an ongoing and in-depth dialogue with both research and development and business development executives at many of the largest manufacturers of biomedical device companies. This interaction gives us a broad view of the short- and long-term needs of these companies for support of both their current and future product lines.

We share gross profit equally with New Scale Technologies, the inventor and manufacturer of the technology. Biophan provides sales and marketing, and a $25,000 quarterly advance, reconcilable against current year sales, to New Scale, which enables New Scale to further develop unique capabilities for the medical market. The motor is already on the market for non-medical applications and evaluation units are being sold to customers around the world. The motor is currently under review by several biomedical device manufacturers of drug pumps and other devices.

On February 5, 2004, we entered into a second stock purchase agreement with SBI Brightline Consulting, LLC that obligates SBI to purchase, upon our election, up to 17,750,000 shares of our common stock for an aggregate purchase price of $25 million. SBI is not obligated to purchase shares pursuant to this stock purchase agreement unless the resale of the shares by SBI is registered under the Securities Act. Only 6,000,000 shares covered by this stock purchase agreement were registered for resale by SBI, because we previously had insufficient authorized shares. SBI is not obligated to purchase the unregistered shares covered by the stock purchase agreement until we have registered the resale of such shares by SBI and then only upon our election. Our stockholders approved the proposal to amend our articles of incorporation to increase the number of authorized shares and we will now decide whether to register additional shares for resale by SBI, which will give us the right to sell such additional shares under the stock purchase agreement. Until the stockholder approval, which allows us to sell shares at the higher $2 per share price, the SBI transaction was less attractive. During the quarter ended August 31, 2004, we sold the first tranche of 2 million shares for $1.2 million.

An additional factor influencing our decision to exercise all or part of the remaining SBI financing involves negotiations with several biomedical device and pharmaceutical companies, which may involve a combination of R&D development and/or licensing payments, as well as a strategic investment in equity in our company. Such an investment, should it occur, may resolve, in whole or in part, our capital requirements for listing on a major stock exchange, as well as provide us with working capital to continue our research, and possible milestone payments. As a result, we intend to be prudent in our exercise of the SBI line, even with its very attractive fixed price aspects. One of the companies we are working with is preparing a term sheet, and one of the terms that is being negotiated will be an equity investment in the company which will require that we issue preferred stock. As a result, we are in the process of calling a special meeting of stockholders to seek approval for reducing the number of authorized common shares by 15 million and establishing an equal number of authorized preferred shares.

Therefore, depending on the number of shares of stock that we sell to SBI under the stock purchase agreement or a potential strategic investment, or a combination thereof, the capital provided by such sales should enable us to satisfy the net worth requirements for a planned stock exchange listing.

We estimate that our current working capital, and proceeds from the sale of our common stock pursuant to the SBI stock purchase agreement already registered or a potential equity investment from a strategic relationship, will be sufficient to satisfy our projected cash requirements over the next 12 months. Our estimate of these cash requirements is as follows:

Research and product development(including R&D and marketing for the ceramic motor and biothermal battery projects, including additional human resources) $1,732,000

Operating expenses, including administrative salaries and benefits, office expenses, rent expense, legal and accounting, publicity, investor relations 2,204,000

Total Cash Requirements $3,936,000

We have adopted and are following three major strategic initiatives for fiscal 2005:

(1) Acquisition of Intellectual Assets, (2) Market Expansion, and (3) Strategic Partnerships.

(1) Biophan currently has an overall estate of 92 patents, inclusive of those assigned and licensed, and including filed applications and allowed and issued patents.

From the perspective of ownership:

o 35 are licensed from Nanoset, LLC, Johns Hopkins University, and Dr. Deborah Chung; these deal with MRI safety and compatibility, as well as MRI contrast agents and other nanoparticles technology.

o 3 are licensed by TE Bio LLC, which is in turn majority controlled by Biophan; these deal with biothermal power technology.

o 1 is a patent applied for by New Scale Technologies, Inc. covering a miniature ceramic motor. Biophan has exclusive marketing and distribution rights for medical applications of this technology.

o 53 are directly assigned to Biophan; these deal with MRI safety and compatibility and a variety of other medical device opportunities.

Of the 92:

o 21 have issued as U. S. patents.

o 7 have been allowed and will issue as patents in the near future.

o 64 are patent applications in various stages of prosecution in the USPTO.

The patents also include those licensed from Nanoset, LLC. Nanoset's technology can be used to reduce image artifacts on implantable and interventional medical devices and for a new class of applications to enhance the uptake, release and monitoring of drugs in medical device coatings. TE Bio is developing our biothermal battery technology.

We are aggressively pursuing internal research and development projects, as well as sourcing leading-edge providers of related technologies. Intellectual property, such as technology solutions and patents, may be developed internally, through joint ventures, licensed in, or purchased. To ensure the continuing value of our intellectual assets, we intend to aggressively defend our patents and licensed technology, both domestically and abroad.

(2) We currently enjoy a leadership position in developing technologies designed to make implanted medical devices, such as pacemakers, safe for use with MRI and other diagnostic imaging tools. We have also developed technologies that allow medical devices to be used for interventional procedures, under MRI, without the heating problems that can cause tissue damage or imaging problems which can obscure the outcome of the procedures. Today most interventional procedures are performed under X-ray, CT scan, or fluoroscopy and expose both physicians and patients to ionizing radiation. Physicians need to wear heavy lead aprons that can cause back problems, etc., and patients are sometimes exposed to substantial radiation doses. If the MRI safety and compatibility issues of interventional devices were solved and devices were on the market, we believe that there would be a significant migration of procedures, over time, to use with MRI.

Based on discussions underway with several biomedical device manufacturers, and MRI manufacturers, both in the U.S. and overseas, we plan to expand the use of the technologies we have developed to make a wider range of devices compatible with MRI. These technologies reduce radio frequency interference, heating, and induced voltages. Since the beginning of 2004, we have expanded our development and partnering activities related to these technologies to include guidewires, stents, drug pumps, biopsy needles and other prosthetic and surgical tool devices, where the lack of MRI compatibility negatively impacts investigational and diagnostic procedures.

Discussions with these device manufacturers indicate a need for, and an interest in, solutions to additional problems based on our technology. We have used both surrogate devices (such as copper rings) and actual manufactured implantable products, in a gel phantom, to demonstrate our ability to accurately image devices and their interior spaces in a manner that could not be done previously. Part of our strategic initiative for the current fiscal year will include expanding our technology offerings to the companies with whom we are already in discussions or collaborating. These arrangements may include payments for R&D, licensing, equipment and materials purchases, milestone payments, as well as possible strategic investments.

An example of our expanding on the use of our nanomagnetic particle coating technology is NanoView. The concept of our NanoView technology is to utilize nanomagnetic particles, a specific type of nanotechnology, as MRI contrast agents to preferentially bind to tissues of diagnostic interest with the goal of improving detail and contrast in MRI diagnostic image processes. We expect NanoView to improve performance in terms of signal intensity and the use of multiple markers, which broadens the applications of MRI imaging. The ability to bind different, distinct markers to different antigens allows the potential for highlighting multiple features of interest, making them differentiable under MRI. We have begun discussions with several manufacturers of contrast agents and others in the diagnostic materials sector.

(3) Leveraging strategic partnerships is vital to our mission. In November, 2003, we announced that we had entered into a joint development agreement with Boston Scientific, a major medical device manufacturer. We have successfully completed the first phase of a multi-phase development plan with Boston Scientific, and we are currently working in the second and third phases of this program. Relationships such as this one help us validate our technology and also develop potential sales channels. We have entered into non-disclosure agreements with a number of major manufacturers of implanted biomedical and related devices. We are discussing with these companies potential strategic partnership arrangements that may include joint development projects, original equipment manufacturing arrangements and licensing agreements.

In November 2003, we recorded $75,000 as a development payment from Boston Scientific for prototype development of a prospective product adaptation. The development activities related to this payment have been completed. We are currently in the second phase of this agreement and have received $225,000 as an advance payment for the second and third phases which are underway. We are in ongoing discussions concerning additional phases of this initiative that, which if completed and successful, may lead to a license for one or more of our technologies in the context of one or more product lines. We are in discussion with Boston Scientific for an expanded relationship involving license fees, milestones and royalties.

Our current strategic plan does not indicate a need for material capital expenditures in the conduct of research and development activities, nor does the plan contemplate any significant change in the number of employees. We currently employ thirteen full-time individuals.

Our plans do not include funding for FDA approvals, as our strategy is to supply solutions to the major biomedical device manufacturers, who will incorporate our technology into their existing and future product lines. It will be the responsibility of these manufacturers to apply for and receive FDA approval of their products. Since our technologies are made of known biocompatible, non-toxic materials, and since we do not change the method by which the devices conduct diagnostic and/or therapeutic functionality, we anticipate reasonable timeframes for our customers to obtain FDA approvals of devices that add our capability for safety and/or image enhancements.



thx cybercoach  

 

 

 

noch lange nicht.Die Biophan wird erstmal aus der Halle gerollt.Abheben wird sie bei der ersten richtigen!!! News  

http://quotes.barchart.com/texadv.asp?sym=biph  

Die steigt und steigt. So langsam seh ich kein Grund mehr warum das so ist...is da was im Busch?  

wurden gestern noch um 17.01 320k gekauft.Na ob da jemand mehr weiß???  

 

und wieder bei Tages hoch geschlossen.Sk 1,22$ und das ohne News und die Hammernews stehen erst noch an...

schönes We allen Investierten  

schaut euch das Video mal an,interessante PR-Action:

The new video, " Biophan 101: Part 2" will focus on two areas: Biophan's biothermal battery technology, which uses body heat to generate electricity for implanted medical devices, and the Company's implantable ceramic motor technology, which is highly precise, safe and image compatible with Magnetic Resonance Imaging (MRI) environments.

Biophan recently announced that its portfolio of technologies has grown to a total of 92 patents and patent applications, owned by Biophan or licensed exclusively from organizations including Johns Hopkins, New Scale Technologies, and Nanoset, LLC.

About Biophan Technologies

Mentioned Last Change
BIPH 1.22 0.03dollars or (2.52%)
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com .



 

Biophan hat einen anderen Status erreicht.Ich bin der Meinung,der Weg zur AMEX ist geebnet.Es ist nur noch eine Frage der Zeit.Für ein KZ in nächster Zeit möchte ich mich zurück haltn,da man schnell an die Wand genagelt werden kann.Ich halte aber noch an meinem Einangsposting fest.Wenn es nicht eintrifft,habe ich es auch nur knapp verfehlt!!!
Fakt,wir sind die letzten Tage massiv gestiegen und werden es moderat ohne News weiter.Wenn sich ein Meldung anbahnt,wird es rasant gehen.Meldungen zu weiteren Patenten und Zusammenarbeiten sind noch offen.Der BSX-Deal ist auch noch offen,der Börsenwechsel (so sicher wie das Amen in der Kirche) ist auch noch offen.
Ich rede nicht von "verhundertfachung" oder "die Kurse sind ein Witz" oder"Megapotential" und ähliches,das überlasse ich anderen :-)))
Nur soviel,die User,die sich Biophan noch nicht angeschaut haben,nehmt euch die Zeit.Nicht umsonst ist eine der angesagtesten NANOTECH-Sitzungen in Verbindung mit Biophan und vorallem ,Leute,nicht umsonst in Germany (FFm)Leute---in Germany!!!

Wir eine komplette Zusammenfassungen aller Fakts,empfehle ich den Konkurrenzthread auf
www.wallstreet-online.de   (Biophan) Hier sind alle Fakten lückenlos in einem kompletten Thread von Freunden zusammengefügt und gesammelt.

Allen ein schönes WE
gruß AIDA  

Die positiven Meinungen zu Biophan häufen sich.Jetzt wird schon von Vergleichbarem geredet.Vergleiche mit "Medtronic",vom Potential,werden angesprochen.
Es sollte jedem klar sein,Biophan Technologie ist kein Short Term.Die Bezeichnung liegt auf "Medium" bis "Long" Term